{"id":"NCT01926782","sponsor":"Regeneron Pharmaceuticals","briefTitle":"Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab (REGN727/ SAR236553) in Patients With Primary Hypercholesterolemia (ODYSSEY CHOICE 1)","officialTitle":"A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab in Patients With Primary Hypercholesterolemia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-09","primaryCompletion":"2014-09","completion":"2015-04","firstPosted":"2013-08-21","resultsPosted":"2017-03-21","lastUpdate":"2017-03-21"},"enrollment":803,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Hypercholesterolemia"],"interventions":[{"type":"DRUG","name":"Placebo (for alirocumab)","otherNames":[]},{"type":"DRUG","name":"Alirocumab","otherNames":["SAR236553","REGN727","Praluent"]},{"type":"DRUG","name":"Statin","otherNames":[]}],"arms":[{"label":"Placebo Q2W","type":"PLACEBO_COMPARATOR"},{"label":"Alirocumab 75 mg/ Up 150 mg Q2W","type":"EXPERIMENTAL"},{"label":"Alirocumab 300 mg/ Up 150 mg Q4W","type":"EXPERIMENTAL"}],"summary":"To determine the efficacy, long-term safety, and tolerability of alirocumab 300 mg every 4 weeks (Q4W), in comparison with placebo, as well as its potential as a starting regimen. The dose regimen of 75 mg every 2 weeks (Q2W), as used in other studies, was added as a calibrator.","primaryOutcome":{"measure":"Percent Change From Baseline in Calculated LDL-C in Participants Not Receiving Concomitant Statin Therapy - ITT Analysis","timeFrame":"From Baseline to Week 24","effectByArm":[{"arm":"Placebo Q2W Without Concomitant Statin","deltaMin":-0.3,"sd":2.7},{"arm":"Alirocumab 75 mg Q2W/Up 150 mg Q2W Without Concomitant Statin","deltaMin":-50.2,"sd":3.7},{"arm":"Alirocumab 300 mg Q4W/Up 150 mg Q2W Without Concomitant Statin","deltaMin":-52.7,"sd":1.9}],"pValues":[{"comp":"OG000 vs OG002","p":"<0.0001"},{"comp":"OG000 vs OG002","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":83,"countries":["United States","Bulgaria","Canada","Hungary","Israel","Norway","Slovakia","United Kingdom"]},"refs":{"pmids":["32928709","31166599","27639753"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":33,"n":229},"commonTop":["Injection site reaction","Nasopharyngitis","Upper respiratory tract infection","Arthralgia","Headache"]}}